Evidence map›Paper›PMID 39688699›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2025

Preclinical evaluation of 64Cu/177Lu-labelled anti-CD30 monoclonal antibody for theranostics in CD30-positive lymphoma.

Xu Yang, Jun Liu, Cuicui Li, Lingling Zheng, Xia Lu, Ziang Zhou, Xianyu Zhu, Jianhua Gong, Qingfang Miao, Jigang Yang

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Xu YangDepartment of Nuclear Medicine, Beijing Friendship Hospital, Capital Medical University, 95 Yong An Road, Xi Cheng District, Beijing, 100050, China.
Jun LiuDepartment of Nuclear Medicine, Beijing Friendship Hospital, Capital Medical University, 95 Yong An Road, Xi Cheng District, Beijing, 100050, China.
Cuicui LiDepartment of PET-CT Centre, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, 250117, Shandong, China.
Lingling ZhengDepartment of Nuclear Medicine, Beijing Friendship Hospital, Capital Medical University, 95 Yong An Road, Xi Cheng District, Beijing, 100050, China.
Xia LuDepartment of Nuclear Medicine, Beijing Friendship Hospital, Capital Medical University, 95 Yong An Road, Xi Cheng District, Beijing, 100050, China.
Ziang ZhouDepartment of Nuclear Medicine, Beijing Friendship Hospital, Capital Medical University, 95 Yong An Road, Xi Cheng District, Beijing, 100050, China.
Xianyu ZhuDepartment of Nuclear Medicine, Beijing Friendship Hospital, Capital Medical University, 95 Yong An Road, Xi Cheng District, Beijing, 100050, China.
Jianhua GongNHC Key Laboratory of Biotechnology of Antibiotic, Department of Oncology, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College,, Courtyard No. 2, Nanwei Rd., Xicheng Dist, Beijing, 100050, China. ann_gong@imb.pumc.edu.cn.
Qingfang MiaoNHC Key Laboratory of Biotechnology of Antibiotic, Department of Oncology, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College,, Courtyard No. 2, Nanwei Rd., Xicheng Dist, Beijing, 100050, China. miaoqf@imb.pumc.edu.cn.
Jigang YangDepartment of Nuclear Medicine, Beijing Friendship Hospital, Capital Medical University, 95 Yong An Road, Xi Cheng District, Beijing, 100050, China. yangjigang@ccmu.edu.cn.ORCID 0000-0002-0538-7676

Funding

Beijing Friendship Hospital Seed Project of Capital Medical University YYZZ202338Beijing Natural Science Foundation 7234359Beijing Postdoctoral Research Foundation 364329China National Postdoctoral Program GZC20231753National Natural Science Foundation of China 82202206National Natural Science Foundation of China 82272034National Natural Science Foundation of China 82302235
6 · The paper itself

Abstract

purposeCD30 serves as an ideal therapeutic target for lymphoma, but its variable expression and high relapse rate pose challenges in targeted therapy. This study aims to label the anti-CD30 monoclonal antibody with

methodsCD30 binding kinetics of anti-CD30-IgG (IMB16) were measured by Biolayer interferometry (BLI). Western blotting screened lymphoma cell lines for CD30 expression. Flow cytometry and immunofluorescence validated the specific binding of IMB16. IMB16 was conjugated to p-SCN-Bn-NOTA(NOTA) and p-SCN-Bn-DOTA(DOTA) for radiolabeling with

resultsIMB16 had a strong binding affinity to CD30 according to the BLI. Western blotting revealed high CD30 expression in Karpas299 cells and negative expression in Raji cells. Flow cytometry and immunofluorescence confirmed specific binding of IMB16 to CD30 on cell surface. Radiochemical purity of [

conclusionsLabelling IMB16 with

Indexed as

Antibodies, MonoclonalCopper RadioisotopesKi-1 AntigenLutetiumLymphomaRadioisotopesTheranostic NanomedicineAnimalsCell Line, TumorHumansIsotope LabelingMicePositron-Emission TomographyRadioimmunotherapyTissue DistributionAntibodies, MonoclonalCopper-64Copper RadioisotopesKi-1 AntigenLutetiumLutetium-177RadioisotopesCD30Copper-64Immuno-PETLetetium-177LymphomaRadioimmunotherapyTheranostic

Identifiers

PMID39688699

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.